Core Viewpoint - Zhengye Biology (ZYBT) experienced a stock price increase of 5.28% on August 12, reaching $5.485 per share, with a total market capitalization of $260 million [1]. Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1]. - The net profit attributable to the parent company was 11.31 million RMB, showing a significant decline of 64.04% compared to the previous year [1]. Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1]. - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1].
正业生物上涨5.28%，报5.485美元/股，总市值2.60亿美元